Companion Diagnostics are poised to revolutionize the diagnostics industry.  The market is finally moving out of the lab and into the clinic.  Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future.  But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing.  Find out the latest outlook for this important market.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities.  And some players are already taking the lead.  It is a dynamic market situation with enormous opportunity.  Diagnostic companies are trying to back the right horse.  The science is racing forward.  And the cost of molecular diagnostics continues to fall.

" Companion Diagnostic Markets, the future of diagnostics.  By Funding Source and Application with customized forecasting/analysis, Covid Updates, and Executive and Consultant Guides 2020-2024" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail.   Forecast demand for new testing regimes or technologies.  Make research investment decisions.  Specific growth and market size estimates for your area of interest is normally provided without additional charges.  Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.  Again, assistance in using the information is normally provided without additional charges.  

The report includes detailed breakouts for 18 Countries and 4 Regions.  A detailed breakout for any country or specific area in the world is available to purchasers of the report.